Inhibrx Announces Participation in Upcoming Scientific Conferences

/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare...

Related Keywords

Colorado ,United States ,Boston ,Massachusetts ,Canada ,Vancouver ,British Columbia ,American ,Bryan Becklund ,Vivek Subbiah ,Pharmacometrics Aco ,Robin Lewisl Jones ,Santp Chawla ,Bristol Myers Squibb ,Nehalj Lakhani ,Sharvari Bhagwat ,Prnewswire Inhibrx Inc ,Society For Immunotherapy Of Cancer ,Connective Tissue Oncology Society ,Inhibrx Inc ,Nasdaq ,Fusion Protein ,Molecular Targeted Cytokine ,Potentiates Anti Tumor ,Tissue Oncology Society ,Updated Efficacy ,Tetravalent Death Receptor ,Present Virtual Poster Presentation ,Ewing Sarcoma ,Preclinical Rationale ,Combination Expansion ,Placebo Controlled Phase ,Metastatic Conventional ,Robin Lewis ,Media Contact ,